Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments

SC Li - Current Opinion in Rheumatology, 2022 - journals.lww.com
Methotrexate treatment has greatly improved outcome for most jLS patients but a substantial
portion have refractory cutaneous and/or extracutaneous disease. Treatment response …

Morbidity and disability in juvenile localized scleroderma: the case for early recognition and systemic immunosuppressive treatment

SC Li, KM O'Neil, GC Higgins - The Journal of Pediatrics, 2021 - jpeds.com
Suzanne C. Li, MD, PhD1, Kathleen M. O'Neil, MD2, and Gloria C. Higgins, MD, PhD3
Juvenile localized scleroderma, also called morphea, is a chronic autoimmune and fibrosing …

Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma

SC Li, GC Higgins, M Chen, KS Torok… - …, 2021 - academic.oup.com
Objective The aim of this study was to evaluate factors associated with extracutaneous
involvement (ECI) in juvenile localized scleroderma (jLS). Methods A prospective …

[PDF][PDF] Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale

SC Li, CE Rabinovich, ML Becker… - Arthritis Care & …, 2024 - researchgate.net
Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly
associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures …

Responsiveness to Change of the Morphea Activity Measure in Pediatric Patients

MT García-Romero, HA Brandling-Bennett… - JAMA …, 2024 - jamanetwork.com
Importance Detecting activity of morphea can be complex but is crucial for adequate
treatment and outcome assessment. The Morphea Activity Measure (MAM) was recently …